CA
NZ
UK
AU
IND
US
Novartis AG (NYSE: NVS) shares traded higher following Phase 3 results for remibrutinib in multiple sclerosis, which demonstrated a significant reduction in relapses and brain lesions compared to Sanofi's teriflunomide.
Kala Bio, Inc. (NASDAQ: KALA) entered a non-binding Letter of Intent with Virotek to establish an exclusive U.S. distribution and resellerPartnershipfor Virotek's ophthalmic genetic screening and diagnostic tests.
Stoke Therapeutics, Inc. (NASDAQ: STOK) and Biogen Inc. (NASDAQ: BIIB) revealed four-year open-label extension Phase 1/2a results for zorevunersen in Dravet syndrome, indicating sustained cognitive and behavioral improvements coupled with permanent reductions in seizure occurrences and a clean safety summary.
bioAffinity Technologies, Inc. (NASDAQ: BIAF) is positioning its CyPath Lung test as a noninvasive monitoring tool for patients post-curative treatment to detect recurrence or secondary primary lung cancers.
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) received a reiterated Buy rating and $13 price target from H.C. Wainwright following a Type D meeting where the FDA aligned on the CAD-1005 Phase 3 primary endpoint and placebo-controlled trial design for heparin-induced thrombocytopenia.
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) shares closed down 15% at $3.54 afterNasdaqissued a delisting notice for failure to meet the $35 million market value of listed securities requirement by the August 25 deadline.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares closed down 21% at $6.69 after the company revised the schedule for its Phase 2 FIGHT DMD trial of ifetroban.
Alumis Inc. (NASDAQ: ALMS) announced that its Phase 2b LUMUS trial of envudeucitinib for moderate-to-severe systemic lupus erythematosus failed to meet its primary and secondary endpoints across the general participant population.
RedHill Biopharma Ltd. (NASDAQ: RDHL) shares closed up 36% at $0.90 after the company finalized the divestment of its 70% stake in the Talicia business to an Apotex Health unit for $18 million in upfront capital and potential sales-based milestones totaling $35 million.
Lakewood Amedex, Inc. (NASDAQ: LABT) received a U.S. patent notice of allowance for its antimicrobial compounds, compositions, and therapeutic uses.
Please wait processing your request...